.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,255,092

« Back to Dashboard

Details for Patent: 9,255,092

Title:Polymorph of a pharmaceutical
Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
Inventor(s): Bauer; John F. (Georgetown, KY), Saleki-Gerhardt; Azita (Mettawa, IL), Narayanan; Bikshandarkoil A. (Newton, CT), Chemburkar; Sanjay R. (Gurnee, IL), Patel; Ketan M. (Wheeling, IL), Spiwek; Harry O. (Kenosha, WI), Bauer; Philip E. (Chester Springs, PA), Allen; Kimberly A. (Trevor, WI)
Assignee: AbbVie Inc. (North Chicago, IL)
Filing Date:Oct 14, 2013
Application Number:14/053,311
Claims:1. A composition comprising one or more of amorphous ritonavir and Form II crystalline ritonavir, wherein said composition is prepared by dissolving one or more of Form II crystalline ritonavir and Form I crystalline ritonavir in a solvent, wherein said Form II crystalline ritonavir has characteristic peaks in a powder X-ray diffraction pattern at values of two theta of 8.67.degree..+-.0.1.degree., 9.88.degree..+-.0.1.degree., 16.11.degree..+-.0.1.degree., 16.70.degree..+-.0.1.degree., 17.36.degree..+-.0.1.degree., 17.78.degree..+-.0.1.degree., 18.40.degree..+-.0.1.degree., 18.93.degree..+-.0.1.degree., 20.07.degree..+-.0.1.degree., 20.65.degree..+-.0.1.degree., 21.71.degree..+-.0.1.degree. and 25.38.degree..+-.0.1.degree., and wherein said Form I crystalline ritonavir has characteristic peaks in a powder X-ray diffraction pattern at values of two theta of 3.33.degree..+-.0.1.degree., 6.76.degree..+-.0.1.degree., 8.33.degree..+-.0.1.degree., 14.61.degree..+-.0.1.degree., 16.33.degree..+-.0.1.degree., 16.76.degree..+-.0.1.degree., 17.03.degree..+-.0.1.degree., 18.02.degree..+-.0.1.degree., 18.62.degree..+-.0.1.degree., 19.47.degree..+-.0.1.degree., 19.86.degree..+-.0.1.degree., 20.25.degree..+-.0.1.degree., 21.46.degree..+-.0.1.degree., 23.46.degree..+-.0.1.degree. and 24.36.degree..+-.0.1.degree..

2. The composition of claim 1, wherein said Form II crystalline ritonavir has characteristic peaks in a powder X-ray diffraction pattern at values of two theta of 8.67.degree..+-.0.1.degree., 9.51.degree..+-.0.1.degree., 9.88.degree..+-.0.1.degree., 10.97.degree..+-.0.1.degree., 13.74.degree..+-.0.1.degree., 16.11.degree..+-.0.1.degree., 16.70.degree..+-.0.1.degree., 17.36.degree..+-.0.1.degree., 17.78.degree..+-.0.1.degree., 18.40.degree..+-.0.1.degree., 18.93.degree..+-.0.1.degree., 19.52.degree..+-.0.1.degree., 19.80.degree..+-.0.1.degree., 20.07.degree..+-.0.1.degree., 20.65.degree..+-.0.1.degree., 21.49.degree..+-.0.1.degree., 21.71.degree..+-.0.1.degree., 22.23.degree..+-.0.1.degree., 25.38.degree..+-.0.1.degree., 26.15.degree..+-.0.1.degree. and 28.62.degree..+-.0.1.degree..

3. A composition comprising one or more of amorphous ritonavir and Form II crystalline ritonavir, wherein said composition is prepared by a process which comprises dissolving Form II crystalline ritonavir in a solvent, wherein said Form II crystalline ritonavir has characteristic peaks in a powder X-ray diffraction pattern at values of two theta of 8.67.degree..+-.0.1.degree., 9.88.degree..+-.0.1.degree., 16.11.degree..+-.0.1.degree., 16.70.degree..+-.0.1.degree., 17.36.degree..+-.0.1.degree., 17.78.degree..+-.0.1.degree., 18.40.degree..+-.0.1.degree., 18.93.degree..+-.0.1.degree., 20.07.degree..+-.0.1.degree., 20.65.degree..+-.0.1.degree., 21.71.degree..+-.0.1.degree. and 25.38.degree..+-.0.1.degree..

4. The composition of claim 3, wherein said Form II crystalline ritonavir has characteristic peaks in a powder X-ray diffraction pattern at values of two theta of 8.67.degree..+-.0.1.degree., 9.51.degree..+-.0.1.degree., 9.88.degree..+-.0.1.degree., 10.97.degree..+-.0.1.degree., 13.74.degree..+-.0.1.degree., 16.11.degree..+-.0.1.degree., 16.70.degree..+-.0.1.degree., 17.36.degree..+-.0.1.degree., 17.78.degree..+-.0.1.degree., 18.40.degree..+-.0.1.degree., 18.93.degree..+-.0.1.degree., 19.52.degree..+-.0.1.degree., 19.80.degree..+-.0.1.degree., 20.07.degree..+-.0.1.degree., 20.65.degree..+-.0.1.degree., 21.49.degree..+-.0.1.degree., 21.71.degree..+-.0.1.degree., 22.23.degree..+-.0.1.degree., 25.38.degree..+-.0.1.degree., 26.15.degree..+-.0.1.degree. and 28.62.degree..+-.0.1.degree..
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc